A SURGICAL WINDOW-OF-OPPORTUNITY CLINICAL TRIAL EVALUATING THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH GLIOMA

被引：0

作者：

Singh, Kirit ^{[1
]}

Hotchkiss, Kelly ^{[2
]}

Foster, Matthew ^{[3
]}

Railton, Chelsea ^{[4
]}

Blandford, Emily ^{[2
]}

Thomas, Elizabeth ^{[5
]}

Miller, Elizabeth S. ^{[6
]}

Ashley, David ^{[7
]}

Desjardins, Annick

Friedman, Henry ^{[8
]}

Johnson, Margaret O. ^{[6
]}

Friedman, Allan ^{[9
]}

Keir, Steve ^{[10
]}

Herndon, James ^{[11
]}

Sampson, John ^{[2
]}

Li, Chuan-Yuan ^{[12
]}

Fecci, Peter ^{[9
]}

Patel, Anoop ^{[9
]}

Khasraw, Mustafa ^{[4
]}

机构：

[1] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[2] Duke Univ, Durham, NC USA

[3] Duke Prote & Metabol core, Durham, NC USA

[4] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[5] Duke Univ Brain Tumor Biorepository, Durham, NC USA

[6] Duke Univ, Sch Med, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[7] Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA

[8] Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[9] Duke Univ, Dept Neurosurg, Durham, NC USA

[10] Duke Univ, Sch Med, Durham, NC USA

[11] Duke Canc Inst, Dept Biostat, Durham, NC USA

[12] Duke Canc Inst, Durham, NC USA

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTIM-10

引用

页数：1

共 50 条

[21] Effects of Long-term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome
Henry, Robert R.
Holman, Rury R.
Giugliano, Robert P.
Raal, Frederick J.
Sullivan, David
Honarpour, Narimon
Nelson, Patric
Elliott, Mary
Liu, Thomas
Wasserman, Scott M.
Koren, Michael J.
DIABETES, 2014, 63 : A157 - A157
[22] PCSK9 inhibitor evolocumab meets primary end points in two Phase III studies
Dowdall, Michael
CLINICAL LIPIDOLOGY, 2014, 9 (01) : 16 - 17
[23] EVALUATING PCSK9 INHIBITOR EFFICACY IN MI PATIENTS ON HIGH-INTENSITY STATINS
Almansi, Amjad
Batarseh, Suhel
Hasan, Mohamed
Ghanm, Thoria Ibrahim Essa
Alnajjar, Asmaa Zakria
ATHEROSCLEROSIS, 2024, 399
[24] INHIBITION OF PCSK9 WITH EVOLOCUMAB MODULATES IMMUNE-CELL ACTIVATION IN HIGH-RISK ASCVD PATIENTS -THE METCHNIKOFF CLINICAL TRIAL
Rosenson, Robert S.
Goonewardena, Sascha
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1632 - 1632
[25] Impact of PCSK9 inhibitors Alirocumab and Evolocumab on total & LDL cholesterol in clinical practice
Capps, N.
ATHEROSCLEROSIS SUPPLEMENTS, 2017, 28 : E13 - E13
[26] Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Giugliano, Robert P.
Pedersen, Terje R.
Park, Jeong-Gun
De Ferrari, Gaetano M.
Gaciong, Zbigniew A.
Ceska, Richard
Toth, Kalman
Gouni-Berthold, Ioanna
Lopez-Miranda, Jose
Schiele, Francois
Mach, Francois
Ott, Brian R.
Kanevsky, Estelle
Pineda, Armando Lira
Somaratne, Ransi
Wasserman, Scott M.
Keech, Anthony C.
Sever, Peter S.
Sabatine, Marc S.
LANCET, 2017, 390 (10106): : 1962 - 1971
[27] A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer
Duska, Linda R.
Petroni, Gina R.
Lothamer, Heather
Faust, William, Jr.
Beumer, Jan H.
Christner, Susan M.
Mills, Anne M.
Fracasso, Paula M.
Parsons, Sarah J.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 473 - 482
[28] A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer
Linda R. Duska
Gina R. Petroni
Heather Lothamer
William Faust
Jan H. Beumer
Susan M. Christner
Anne M. Mills
Paula M. Fracasso
Sarah J. Parsons
Cancer Chemotherapy and Pharmacology, 2019, 83 : 473 - 482
[29] Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Sabatine, Marc S.
Leiter, Lawrence A.
Wiviott, Stephen D.
Giugliano, Robert P.
Deedwania, Prakash
De Ferrari, Gaetano M.
Murphy, Sabina A.
Kuder, Julia F.
Gouni-Berthold, Ioanna
Lewis, Basil S.
Handelsman, Yehuda
Pineda, Armando Lira
Honarpour, Narimon
Keech, Anthony C.
Sever, Peter S.
Pedersen, Terje R.
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : 941 - 950
[30] Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
Silla, Alessia
Fogacci, Federica
Punzo, Angela
Hrelia, Silvana
Simoni, Patrizia
Caliceti, Cristiana
Cicero, Arrigo F. G.
ANTIOXIDANTS, 2023, 12 (03)

← 1 2 3 4 5 →